Menopause-Like Woes Hinder Breast Cancer Treatment: Study
One-quarter of patients fail to start or complete recommended therapy, researchers find
URL of this page: http://www.nlm.nih.gov/medlineplus/news/fullstory_135869.html
(*this news item will not be available after 07/11/2013)
Friday, April 12, 2013
FRIDAY, April 12 (HealthDay News) -- Hot flashes and other unpleasant side effects are a major reason one-quarter of breast cancer patients do not start or do not complete their recommended hormone-blocking therapy, a new study finds.
Five years of daily pills -- either tamoxifen or aromatase inhibitors -- is recommended for many women whose breast cancer expresses the hormones estrogen or progesterone. The drugs have been shown to reduce the risk of cancer returning and to extend survival.
Despite such benefits, this study of more than 700 breast cancer patients in Detroit and Los Angeles who were eligible for hormone therapy found that about 11 percent never started treatment and 15 percent stopped it early.
Unpleasant, menopause-type side effects, such as vaginal dryness, hot flashes or joint pain, were the most common reasons women either stopped or never started the therapy.
"We need to develop better ways of supporting women through this therapy," lead study author Christopher Friese, an assistant professor at the University of Michigan School of Nursing, said in a university news release.
Those most likely to complete their hormone therapy were patients who were most worried about their cancer returning and those who already took medication regularly, according to the study, which was published online March 31 in the journal Breast Cancer Research and Treatment.
Patients least likely to begin hormone therapy included those who received less information about hormone therapy, which suggests that doctors need to properly educate patients before treatment begins, the researchers said.
Women who saw a breast cancer surgeon instead of a medical oncologist as their primary follow-up also were less likely to begin hormone therapy.
"It was particularly interesting that greater fear of recurrence was associated in our patient sample with greater adherence to endocrine therapy," study senior study author Dr. Jennifer Griggs, a professor of internal medicine at the University of Michigan Medical School.
"We don't want our patients living under a cloud of fear, so we need to develop creative ways to both reassure and motivate them," said Griggs, a medical oncologist. "This means providing better education about the importance of staying on these medications and partnering with primary care and cancer doctors to help patients manage symptoms."
More than 234,000 Americans will be diagnosed with breast cancer this year and more than 40,000 will die from the disease, the American Cancer Society estimates.
SOURCE: University of Michigan Comprehensive Cancer Center, news release, April 9, 2013Five years of daily pills -- either tamoxifen or aromatase inhibitors -- is recommended for many women whose breast cancer expresses the hormones estrogen or progesterone. The drugs have been shown to reduce the risk of cancer returning and to extend survival.
Despite such benefits, this study of more than 700 breast cancer patients in Detroit and Los Angeles who were eligible for hormone therapy found that about 11 percent never started treatment and 15 percent stopped it early.
Unpleasant, menopause-type side effects, such as vaginal dryness, hot flashes or joint pain, were the most common reasons women either stopped or never started the therapy.
"We need to develop better ways of supporting women through this therapy," lead study author Christopher Friese, an assistant professor at the University of Michigan School of Nursing, said in a university news release.
Those most likely to complete their hormone therapy were patients who were most worried about their cancer returning and those who already took medication regularly, according to the study, which was published online March 31 in the journal Breast Cancer Research and Treatment.
Patients least likely to begin hormone therapy included those who received less information about hormone therapy, which suggests that doctors need to properly educate patients before treatment begins, the researchers said.
Women who saw a breast cancer surgeon instead of a medical oncologist as their primary follow-up also were less likely to begin hormone therapy.
"It was particularly interesting that greater fear of recurrence was associated in our patient sample with greater adherence to endocrine therapy," study senior study author Dr. Jennifer Griggs, a professor of internal medicine at the University of Michigan Medical School.
"We don't want our patients living under a cloud of fear, so we need to develop creative ways to both reassure and motivate them," said Griggs, a medical oncologist. "This means providing better education about the importance of staying on these medications and partnering with primary care and cancer doctors to help patients manage symptoms."
More than 234,000 Americans will be diagnosed with breast cancer this year and more than 40,000 will die from the disease, the American Cancer Society estimates.
HealthDay
Health News Copyright (c) 2013 HealthDay. All rights reserved.
- More Health News on:
- Breast Cancer
- Cancer--Living with Cancer
No hay comentarios:
Publicar un comentario